Navigation Links
2012 Gastroinstestinal Cancers Symposium reveals new advances aimed at improving treatment, prognosis and detection of GI cancers
Date:1/17/2012

ALEXANDRIA, Va. New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.

Four important studies were highlighted today in a live presscast:

1)Biomarkers Promising for Detecting Barrett's Esophagus Patients at High Risk for Esophageal Cancer: Newly found biomarkers could eventually improve early detection of esophageal cancer in patients with Barrett's esophagus (BE), a condition that significantly increases esophageal cancer risk. Using a special microscope, researchers identified three optical biomarkers in cells of the esophagus lining, which enabled them to stratify patients' risks of progressing to cancer.

2) New Test Shows Promise for Detecting Early Stage Pancreatic Cancer: A new blood-based biomarker test correctly identified nearly two-thirds of patients with early stage pancreatic cancer, which has historically been extremely difficult to detect. When combined with another tumor marker commonly used to monitor disease progression, the new test found 85 percent of patients with pancreatic cancer.

3) Study Finds Prognostic Factors for Rare Neuroendocrine Tumors, Suggests Everolimus May Be More Beneficial Than Previously Shown: Researchers re-analyzing the results of a large phase III study of patients with advanced neuroendocrine tumors (NET) found certain factors predict which individuals are at greatest risk for neuroendocrine tumor progression and more likely to need active therapy. The re-analysis also showed that combining the drug everolimus (Afinitor) with another drug, octreotide, halted tumor growth for a longer period that previously shown, compared to octreotide alone.

4) Multi-Targeted Drug Improves Survival in Certain Patients with Metastatic Colorectal Cancer: An international phase III trial showed that single-agent treatment with the investigational drug regorafenib significantly improves survival and delays cancer progression in patients with metastatic colorectal cancer that has progressed despite other approved treatments, as compared to treatment with placebo and supportive care. Regorafenib is a novel, oral agent that targets multiple biological pathways involved in cancer development and growth.

"Research continues to focus on improving the lives of patients with gastrointestinal cancers in a number of ways, as we better understand how cancer develops and progresses, and develop new therapies and methods of early detection," said Morton Kahlenberg, MD, who moderated the presscast. "At this conference, we will see the results of new studies showing novel approaches to earlier detection and treatment in some of our deadliest and hardest to treat cancers."

Gastrointestinal cancers include those of the colon/rectum, stomach, pancreas, esophagus, small intestine, anus and other digestive organs. In 202, nearly 285,000 people in the U.S. will be diagnosed with these cancers and more than 142,000 will die from them.*


'/>"/>

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Gene links rare and unrelated cancers
2. Wistar receives $4.7 million to develop drug against Epstein-Barr virus-related cancers
3. Key genetic error found in family of blood cancers
4. A gene that protects against colorectal cancers
5. Heart drug may be effective for managing certain cancers: Queens University study
6. Two New Drug Combos May Fight Advanced Breast Cancers
7. Family Tree May Affect Diagnosis Age in Some Breast Cancers
8. British Screening Program Finding More Early Stage Colon Cancers
9. HIV Patients at Heightened Risk for Certain Cancers
10. BRAF addiction of thyroid cancers makes them therapeutically vulnerable
11. New drug combo targets multiple cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology: